Comments
Lupin has launched generic Lanthanum Carbonate chewable tablets used for reducing serum phosphate in patients with end-stage kidney disease in the American market.
The company has launched Lanthanum Carbonate chewable tablets 500 mg (base), 750 mg (base), and 1000 mg (base) after its partner Natco received an approval from the United States Food and Drug Administration (USFDA) for them.
Natco’s tablets are generic versions of Shire Development LLC’s Fosrenol chewable tablets in the same strengths, it added.
Lupin and Natco had entered into an agreement on September 1, 2008 to jointly commercialise generic versions of Fosrenol chewable tablets, the company said.
The tablets are indicated to reduce serum phosphate in patients with end stage renal disease (ESRD), it added.
The company’s cumulative filings with the USFDA now stand at 368. It has received approvals for 222 products, while approvals for 146 product filings are pending, Lupin said.
Shares of Lupin were trading 0.55 per cent higher at Rs 992.40 per scrip on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.